Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) - Jul 21, 2022 - "Rhenium-186 NanoLiposome (186RNL), a novel radiotherapy in development for several rare cancer targets...The Company's principal investigator will provide a full data update on the Phase 1/2a ReSPECT-GBM dose escalation clinical trial at the European Society of Medical Oncology Meeting in Paris France, September 9-13, 2022."
P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology
|